Anti-CDCA8 / Cell division cycle-associated protein 8 / Borealin

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. CDCA8 antibody recognizes Cell division cycle-associated protein 8, also known as Borealin, a core component of the chromosomal passenger complex (CPC) that governs chromosome segregation, spindle assembly, and cytokinesis. Encoded by the CDCA8 gene on chromosome 1p34.3, this protein interacts with Aurora B kinase, INCENP, and Survivin to form a functional complex that ensures accurate mitotic progression. Borealin is essential for proper kinetochore-microtubule attachment, spindle checkpoint activation, and correction of mitotic errors, thereby safeguarding genomic stability during cell division.During mitosis, Borealin localizes to centromeres in metaphase and relocates to the spindle midzone during anaphase, coordinating the transition from chromosome alignment to cytokinesis. Loss of CDCA8 function results in chromosome missegregation, lagging chromatids, and multinucleation, phenotypes commonly associated with aneuploidy and cancer. Expression of CDCA8 peaks during the G2/M phase, reflecting its cell cycle-dependent regulation. Overexpression has been documented in a range of malignancies including breast, lung, and colorectal cancers, correlating with poor prognosis and high proliferative indices.The CDCA8 antibody is widely used in cell cycle and cancer research to detect Borealin localization and expression dynamics. Immunofluorescence analysis with this antibody reveals distinct centromeric staining during metaphase and midbody localization in late mitosis. Western blotting identifies a 35 kilodalton band corresponding to the full-length protein. Because the chromosomal passenger complex regulates essential mitotic checkpoints, the CDCA8 antibody provides a critical tool for studying mechanisms of mitotic fidelity and tumorigenesis.CDCA8 cooperates with Aurora B to phosphorylate substrates involved in spindle tension sensing and cytokinesis. Disruption of this interaction impairs CPC activity and leads to mitotic failure. Borealin's ability to bind DNA through its N-terminal domain and oligomerize via its coiled-coil region enables structural stability of the CPC. Inhibition or knockdown of CDCA8 sensitizes tumor cells to microtubule-targeting drugs, highlighting its potential as a therapeutic target. The antibody thus supports translational research exploring CPC inhibitors and mitotic checkpoint modulators in cancer therapy.In developmental biology, CDCA8 is required for proper cell division during embryogenesis and organogenesis. The CDCA8 antibody facilitates identification of proliferating cells in rapidly dividing tissues and embryonic stem cell cultures. NSJ Bioreagents provides this antibody validated for its applications, ensuring consistent results in mitotic and oncogenic studies.